Skip to main content
Robert Strieter, MD, Pulmonology, Falmouth, MA, University of Virginia Medical Center

RobertMartinStrieterMD

Pulmonology • Falmouth, MA

Critical Care Medicine, Pleural Disease

Consultant

Join to view full profile

Dr. Strieter is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Strieter's full profile

Already have an account?

Summary

  • Dr. Strieter specializes in internal and pulmonary medicine. He was the Global Head of Translational Medicine for Respiratory Diseases at the Novartis Institutes for Biomedical Research. He is Professor Emeritus and former Professor and Chair, Department of Medicine, UVA School of Medicine, previous Professor and Chief of Pulmonary and Critical Care Medicine at UCLA, and previous Professor of Internal Medicine at the University of Michigan. His research has focused on inflammation/immunology related to pulmonary fibrosis, cancer, acute lung injury, lung transplantation, and adult progenitor cell biology. He is a member of the ASCI, AAP, and ATS. He is a Master of the ACP, a Fellow of the ACCP, a Fellow of the RCP-London, and Fellow of the AAAS. He holds ten patents, co-edited two books; and has published 89 book chapters and more than 570 peer-reviewed publications. His H-index is 131, and his work has been cited >50,000 times. He has received several scientific grants and awards, including NIH R01s, and Recognition for Scientific Accomplishments from the ATS. Thompson ISI In-Cites has listed him in the top 100 most cited scientists in Immunology (1992-2007); and he has been listed as one of 400 highly influential biomedical researchers (Eur J Clin Invest 2013; 43:1339-1365).

    In his previous role as Global Head, he oversaw discovery/profiling translational medicine experts (MDs) that performed early exploratory and profiling studies. In addition, he was Co-chair of the respiratory disease area decision board that directed and governed early drug development from the level of target/pathway evaluation to tool compound discovery/HTS to pharmacology/Med/Chem optimization to compound characterization to selection for proof of concept to first in human (Ph1a) to proof of concept studies in specific disease indications.

    In his current role, he is available for consultation relevant to early drug development with expertise related to innate and adaptive immunology.

Education & Training

  • University of Michigan Health System
    University of Michigan Health SystemFellowship, Pulmonary Disease and Critical Care Medicine, 1986 - 1989
  • St Joseph Mercy Ann Arbor
    St Joseph Mercy Ann ArborResidency, Internal Medicine, 1983 - 1986
  • Michigan State University College of Human Medicine
    Michigan State University College of Human MedicineClass of 1983

Certifications & Licensure

  • VA State Medical License
    VA State Medical License 2006 - 2020
  • CA State Medical License
    CA State Medical License 1999 - 2019

Awards, Honors, & Recognition

  • Fellow, American Association for Advancement of Science AAAS
  • FCCP American College of Chest Physicians
  • MACP American College of Physicians
  • Join now to see all

Publications & Presentations

PubMed

Grant Support

  • Fibrocytes In Human Pulmonary FibrosisNational Heart, Lung, And Blood Institute2011
  • Fibrocytes In The Pathogenesis Of Sickle Cell Lung DiseaseNational Heart, Lung, And Blood Institute2010
  • CXC Chemokines In CancerNational Cancer Institute2007–2010
  • Chemokines And Fibrocytes In Acute Lung InjuryNational Heart, Lung, And Blood Institute2006–2009
  • CXC Chemokines In CancerNational Cancer Institute2006
  • Chemokines And Fibrocytes In Acute Lung InjuryNational Heart, Lung, And Blood Institute2005–2006
  • Pulmonary And Critical Care Medicine Training ProgramNational Heart, Lung, And Blood Institute2003–2005
  • SCOR In Pathology Of Fibrotic Lung DiseaseNational Heart, Lung, And Blood Institute2002–2005
  • CXC Chemokine Regulation Of Angiogenesis In CancerNational Cancer Institute2000–2005
  • Angiogenesis In Acute Lung InjuryNational Heart, Lung, And Blood Institute2001–2004
  • Developmental Research ProgramNational Cancer Institute2001–2002
  • Chemokine Regulation Of Angiogenesis In Lung CancerNational Cancer Institute2001–2002
  • CXC Chemokines Regulate Angiogenesis In ARDSNational Heart, Lung, And Blood Institute1999–2002
  • SCOR In Pathology Of Fibrotic Lung DiseaseNational Heart, Lung, And Blood Institute2001
  • CXC Chemokines In Pulmonary FibrosisNational Heart, Lung, And Blood Institute1997–2001
  • Core--TissueNational Heart, Lung, And Blood Institute1997–2001
  • SCOR On Acute Lung InjuryNational Heart, Lung, And Blood Institute1999
  • C-X-C Chemokines And Lung CancerNational Cancer Institute1995–1998
  • TNF And ICAM-1 And Lung Allograft RejectionNational Heart, Lung, And Blood Institute1993–1997
  • Novel Neutrophil Chemotaxin And Lung InjuryNational Heart, Lung, And Blood Institute1994
  • Role Of A Novel Neutrophil Chemotaxin In Lung InjuryNational Heart, Lung, And Blood Institute1990–1993

Hospital Affiliations

Dr. Robert Strieter, Dr. Robert Strieter, MD, Dr. R Strieter, Dr. Robert Martin Strieter